FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283068139> ?p ?o ?g. }

• W4283068139 endingPage "889.e17" @default.
• W4283068139 startingPage "889.e1" @default.
• W4283068139 abstract "Although prophylactic tranexamic acid administration after cesarean delivery resulted in a lower incidence of calculated estimated blood loss of >1000 mL or red cell transfusion by day 2, its failure to reduce the incidence of hemorrhage-related secondary clinical outcomes (TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery trial) makes its use questionable. The magnitude of its effect may differ in women at higher risk of blood loss, including those with multiple pregnancies.This study aimed to compare the effect of tranexamic acid vs placebo to prevent blood loss after cesarean delivery among women with multiple pregnancies.This was a secondary analysis of the TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery trial data, a double-blind, randomized controlled trial from March 2018 to January 2020 in 27 French maternity hospitals, that included 319 women with multiple pregnancies. Women with a cesarean delivery before or during labor at ≥34 weeks of gestation were randomized to receive intravenously 1 g of tranexamic acid (n=160) or placebo (n=159), both with prophylactic uterotonics. The primary outcome was a calculated estimated blood loss of >1000 mL or a red blood cell transfusion by 2 days after delivery. The secondary outcomes included clinical and laboratory blood loss measurements.Of the 4551 women randomized in this trial, 319 had a multiple pregnancy and cesarean delivery, and 298 (93.4%) had primary outcome data available. This outcome occurred in 62 of 147 women (42.2%) in the tranexamic acid group and 67 of 152 (44.1%) receiving placebo (adjusted risk ratio, 0.97; 95% confidence interval, 0.68-1.38; P=.86). No significant between-group differences occurred for any hemorrhage-related clinical outcomes: gravimetrically estimated blood loss, provider-assessed clinically significant hemorrhage, additional uterotonics, postpartum blood transfusion, arterial embolization, and emergency surgery (P>.05 for all comparisons).Among women with a multiple pregnancy and cesarean delivery, prophylactic tranexamic acid did not reduce the incidence of any blood loss-related outcomes." @default.
• W4283068139 created "2022-06-19" @default.
• W4283068139 creator A5001650037 @default.
• W4283068139 creator A5006946714 @default.
• W4283068139 creator A5010301916 @default.
• W4283068139 creator A5018270559 @default.
• W4283068139 creator A5021787063 @default.
• W4283068139 creator A5021867458 @default.
• W4283068139 creator A5022386988 @default.
• W4283068139 creator A5028069517 @default.
• W4283068139 creator A5029191629 @default.
• W4283068139 creator A5032039889 @default.
• W4283068139 creator A5032606627 @default.
• W4283068139 creator A5035416209 @default.
• W4283068139 creator A5037923520 @default.
• W4283068139 creator A5039668351 @default.
• W4283068139 creator A5040973622 @default.
• W4283068139 creator A5047276564 @default.
• W4283068139 creator A5048837610 @default.
• W4283068139 creator A5049913129 @default.
• W4283068139 creator A5051610150 @default.
• W4283068139 creator A5052004467 @default.
• W4283068139 creator A5055431095 @default.
• W4283068139 creator A5059256161 @default.
• W4283068139 creator A5062343791 @default.
• W4283068139 creator A5064390041 @default.
• W4283068139 creator A5065143968 @default.
• W4283068139 creator A5078408177 @default.
• W4283068139 creator A5078722840 @default.
• W4283068139 creator A5079244535 @default.
• W4283068139 creator A5082513352 @default.
• W4283068139 creator A5084988646 @default.
• W4283068139 creator A5086343964 @default.
• W4283068139 creator A5087353973 @default.
• W4283068139 creator A5088069106 @default.
• W4283068139 creator A5090138136 @default.
• W4283068139 creator A5090223417 @default.
• W4283068139 creator A5090366562 @default.
• W4283068139 creator A5090412856 @default.
• W4283068139 creator A5090430182 @default.
• W4283068139 date "2022-12-01" @default.
• W4283068139 modified "2023-10-18" @default.
• W4283068139 title "Tranexamic acid for the prevention of blood loss after cesarean among women with twins: a secondary analysis of the TRAnexamic Acid for Preventing Postpartum Hemorrhage Following a Cesarean Delivery randomized clinical trial" @default.
• W4283068139 cites W1131120625 @default.
• W4283068139 cites W1700218291 @default.
• W4283068139 cites W1978293433 @default.
• W4283068139 cites W2082571090 @default.
• W4283068139 cites W2101141558 @default.
• W4283068139 cites W2107339086 @default.
• W4283068139 cites W2121527790 @default.
• W4283068139 cites W2162249417 @default.
• W4283068139 cites W2171542172 @default.
• W4283068139 cites W2252267213 @default.
• W4283068139 cites W2516350590 @default.
• W4283068139 cites W2528573692 @default.
• W4283068139 cites W2530652545 @default.
• W4283068139 cites W2537836444 @default.
• W4283068139 cites W2539290297 @default.
• W4283068139 cites W2607412037 @default.
• W4283068139 cites W2607870311 @default.
• W4283068139 cites W2747300913 @default.
• W4283068139 cites W2767208517 @default.
• W4283068139 cites W2888667478 @default.
• W4283068139 cites W2937036283 @default.
• W4283068139 cites W2945367743 @default.
• W4283068139 cites W2958052131 @default.
• W4283068139 cites W3003940593 @default.
• W4283068139 cites W3169998561 @default.
• W4283068139 cites W3176554556 @default.
• W4283068139 cites W3208524975 @default.
• W4283068139 cites W3210267503 @default.
• W4283068139 cites W3216115139 @default.
• W4283068139 cites W4200311115 @default.
• W4283068139 cites W4211043869 @default.
• W4283068139 cites W4211254429 @default.
• W4283068139 cites W4237539137 @default.
• W4283068139 cites W957262471 @default.
• W4283068139 doi "https://doi.org/10.1016/j.ajog.2022.06.019" @default.
• W4283068139 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35724759" @default.
• W4283068139 hasPublicationYear "2022" @default.
• W4283068139 type Work @default.
• W4283068139 citedByCount "5" @default.
• W4283068139 countsByYear W42830681392022 @default.
• W4283068139 countsByYear W42830681392023 @default.
• W4283068139 crossrefType "journal-article" @default.
• W4283068139 hasAuthorship W4283068139A5001650037 @default.
• W4283068139 hasAuthorship W4283068139A5006946714 @default.
• W4283068139 hasAuthorship W4283068139A5010301916 @default.
• W4283068139 hasAuthorship W4283068139A5018270559 @default.
• W4283068139 hasAuthorship W4283068139A5021787063 @default.
• W4283068139 hasAuthorship W4283068139A5021867458 @default.
• W4283068139 hasAuthorship W4283068139A5022386988 @default.
• W4283068139 hasAuthorship W4283068139A5028069517 @default.
• W4283068139 hasAuthorship W4283068139A5029191629 @default.
• W4283068139 hasAuthorship W4283068139A5032039889 @default.
• W4283068139 hasAuthorship W4283068139A5032606627 @default.
• W4283068139 hasAuthorship W4283068139A5035416209 @default.
• W4283068139 hasAuthorship W4283068139A5037923520 @default.

• next